- Q1-Q3 2023 with stable revenues of € 7.2 million (Q1-Q3 2022: € 7.1 million)
- Marinosolv: progress in business development for Budesolv and Tacrosolv with several interested parties
- Carragelose: High demand for existing virus blockers and expansion of the product portfolio for the allergy and lifestyle growth markets
- Outlook: Weaker full year 2023 expected, but strong growth pipeline for 2024 and beyond
The full press release is available as download here: